Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Advanced Malignant Solid Neoplasm

Advanced Malignant Solid Neoplasm

47

Pipeline Programs↗

39

Active Trials↗

21

Companies Involved↗

Advanced Malignant Solid Neoplasm is a moderately active landscape with 47 programs across 21 companies. The most active players are RasCal Therapeutics, Inc.. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

15/100

Mech. Concentration

4/100

Completion Rate

0/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

RasCal Therapeutics, Inc.

1 program

Pipeline

Programs by Phase

Preclinical8

Axatilimab

Syndax Pharmaceuticals

Retifanlimab

Incyte

Entinostat

Syndax Pharmaceuticals

Temozolomide

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 19

RSC-1255 Dose Expansion

RasCal Therapeutics, Inc.

Epha2-Targeting DOPC-Encapsulated Sirna

M.D. Anderson Cancer Center

TR-002

University of California, Davis

Tuvusertib

EMD Serono Research & Development Institute, Inc.

Copanlisib Hydrochloride

National Cancer Institute (NCI)

Phase 229

Binimetinib

Pfizer

Paclitaxel

Teva

Pembrolizumab

Merck & Co.

BET Bromodomain Inhibitor ZEN-3694

National Cancer Institute (NCI)

Talazoparib

Pfizer

Phase 31

Olanzapine

MODAG GmbH

Approved

No programs

Analysis

Modality Breakdown

78%

Small molecule

36 of 46 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 46 classified programs, each share of the total. Modality classified for 98% of 47 pipeline programs.

Analysis

Trial Status

42

clinical trials

Recruiting19 · 45%

Active, not recruiting18 · 43%

Terminated3 · 7%

Enrolling by invitation1 · 2%

Not yet recruiting1 · 2%

Clinical Trials

Trial Activity

42 trials

Modular Phase 1B Hypothesis-Testing, Biomarker-Driven, Talazoparib Combination Trial (TalaCom)

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT04693468·111 enrolled

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05564377·2,900 enrolled

ECHO Telementoring to Improve Quality Palliative Care in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04984551·312 enrolled

DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT03907475·115 enrolled

Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06311214·500 enrolled

Community-Engaged Pilot Testing of Talking About Cancer (TAC) to Improve Engagement in Advance Care Planning

Recruiting·FFred Hutchinson Cancer Center·Preclinical·NCT07141407·80 enrolled

A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination With the ATR Inhibitor Tuvusertib (M1774)

Recruiting·National Cancer Institute (NCI)·Phase 1·NCT05687136·66 enrolled

Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05327010·88 enrolled

Planning Advance Care Together (PACT) to Improve Engagement in Advance Care Planning

Recruiting·FFred Hutchinson Cancer Center·Preclinical·NCT04515810·400 enrolled

Pilot Study of CBX-12 Pharmacodynamics in Patients With Advanced Solid Tumors

Recruiting·National Cancer Institute (NCI)·Phase 1·NCT05691517·35 enrolled

A Phase 1 Study of ZEN003694 in Combination With Binimetinib in Solid Tumors With RAS Pathway Alterations and Triple Negative Breast Cancer

Recruiting·National Cancer Institute (NCI)·Phase 1·NCT05111561·42 enrolled

A Phase 1/2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774

Recruiting·National Cancer Institute (NCI)·Preclinical·NCT05691491·42 enrolled

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT05039632·40 enrolled

ACTO: A Phase II, Randomized, Placebo-Controlled Study Evaluating Olanzapine in the Management of Cancer Cachexia

Recruiting·OOHSU Knight Cancer Institute·Phase 2·NCT05705492·66 enrolled

A Phase 1 Study of Bisaminoquinoline Derivative (TR-002) for Injection for Advanced Treatment-Refractory Solid Tumors

Recruiting·UUniversity of California, Davis·Phase 1·NCT07189195·52 enrolled

Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)